Women Die of Heart Disease More Than All Cancers Combined. Here Is Why Nobody Told You.

Cardiovascular disease kills one in three women in the United States, more than all cancers combined, including breast, lung, ovarian, uterine, and pancreatic cancers added together. Yet only 44% of women recognize this as their leading cause of death. In 2023, the CDC recorded 304,970 female deaths from heart disease compared to roughly 43,000 from breast cancer. The knowledge gap is the first lethal gap.

Your doctor told you to get a mammogram. Nobody mentioned the thing that is three times more likely to kill you.

She is 48. Healthy weight. No smoking. Three mammograms in the last decade, each one a ritual of anxiety and relief. She has never had an ApoB test. She has never had a coronary calcium scan. Nobody has ever asked her about her pregnancy history as a cardiac risk factor. She is the statistical norm.

This article exists because the system that screened her breasts forgot to screen her arteries.

The Math Nobody Showed You

One in three women dies of cardiovascular disease Roth 2016. One in thirty-one dies of breast cancer. (Honesty: 5/Solid)

In 2023, the CDC recorded 304,970 female deaths from heart disease in the United States. That is roughly one in every five female deaths overall, and the leading cause across all races combined. Breast cancer killed approximately 43,000 women in the same year. The gap is not close. It is a chasm.

The World Heart Federation reports that cardiovascular disease causes 30% of female deaths globally, more than twice the toll of all cancers combined Vogel 2021. (Honesty: 5/Solid)

And yet, the Women’s Heart Alliance and American Heart Association consistently find that only 44 to 56% of women correctly identify heart disease as their leading cause of death Cushman 2021. The other half think it is breast cancer.

This is not a small error. A woman who does not know she is the population at risk cannot advocate for screening, cannot question a dismissive symptom evaluation, and cannot weigh her own risk-benefit math.

Women don’t die from what they have. Women die from what they hold. They hold normal-looking lipid panels with elevated ApoB. They hold a preeclampsia history nobody asked about. They hold a perimenopause blood pressure rise that gets blamed on stress. They hold the assumption that breast cancer is the threat because that is the threat anyone bothered to name.

Why You Were Never Told

The exclusion was structural. Until the 1993 NIH Revitalization Act required inclusion of women in federally funded clinical research, most landmark cardiovascular trials enrolled men almost exclusively.

The Framingham Heart Study, launched in 1948, initially studied men. The Physicians’ Health Study, which established aspirin for primary prevention of heart attack, enrolled 22,071 men and zero women. The MRFIT trial on cholesterol and heart disease enrolled 12,866 men. The assumption was simple and wrong: estrogen protected women until they were too old for it to matter, so studying men was studying the disease.

The downstream consequence: an entire generation of cardiologists was trained on male presentation, male mechanism, male pharmacokinetics, and male diagnostic thresholds.

A 2010 analysis by Mosca and colleagues found physicians were significantly less likely to recommend preventive cardiac care for women than for men with identical risk profiles Mosca 2010. Women presenting with chest pain in emergency departments are more likely to be diagnosed with anxiety, sent home, and return with a completed myocardial infarction. (Honesty: 5/Solid)

The awareness campaigns followed the science by decades. The American Heart Association’s Go Red for Women launched in 2004. Breast Cancer Awareness Month began in 1985. The pink ribbon had a 40-year head start, a unified emotional symbol, and a coherent patient advocacy infrastructure. Heart disease is a fragmented category: coronary artery disease, heart failure, arrhythmia, valvular disease, stroke. There is no red ribbon equivalent in public memory.

The funding gap mirrors the awareness gap. The NIH spends roughly twice as much per death on breast cancer research as it does on coronary heart disease research, despite the mortality differential Mikulic 2023. (Honesty: 4/Promising)

The Disease Is Not the Same Disease

This is the most important sentence in the article: female cardiovascular disease is mechanistically different from male cardiovascular disease, and the standard diagnostic toolkit was built for the male version.

In men, the classic pathway is plaque rupture. A large, lipid-rich, focal plaque in a major epicardial coronary artery becomes unstable, ruptures, and forms an occlusive thrombus. The angiogram shows the blockage. The story makes textbook sense.

In women, the pattern is often plaque erosion rather than rupture, with smaller, more diffuse, less obstructive disease that can cause thrombosis without a dramatic angiographic lesion Reynolds 2021. (Honesty: 5/Solid)

Women also have a higher prevalence of INOCA, ischemia with non-obstructive coronary arteries. The large arteries look clean. The small vessels feeding the heart muscle are diseased. Standard stress tests and angiograms, designed to find obstruction in large arteries, miss microvascular disease entirely. A woman with INOCA is often told her workup is “normal” and sent home with a diagnosis of stress, reflux, or anxiety. Her ischemia continues.

Spontaneous coronary artery dissection (SCAD) is a tear in the coronary artery wall that occurs without atherosclerosis. It is overwhelmingly female-predominant and is the leading cause of myocardial infarction in women under 50, particularly in the peripartum period Hayes 2018. It does not look like a man’s heart attack. It is frequently misdiagnosed. (Honesty: 5/Solid)

Takotsubo cardiomyopathy, the so-called broken heart syndrome, presents with chest pain, ECG changes, and elevated troponin that mimic a heart attack. The left ventricle balloons. The coronary arteries are clean. It is 90% female and often triggered by acute emotional or physical stress.

None of this fits the diagnostic algorithm built for a 60-year-old man with a smoking history and a blocked LAD.

The OES Triad

In my practice, I use a clinical framework called The OES Triad to organize female cardiac risk: Obstetric history, Endocrine transition, and Subclinical inflammation. These are the three domains that the standard Framingham-style risk calculator systematically underweights in women.

Obstetric history. Preeclampsia, gestational hypertension, gestational diabetes, preterm birth, and delivery of a small-for-gestational-age infant are all independent predictors of future cardiovascular disease. Preeclampsia alone confers a two- to four-fold long-term risk of chronic hypertension and a doubled risk of ischemic heart disease Wu 2017. Pregnancy is a 40-week cardiovascular stress test, and its abnormal results predict the rest of your life. (Honesty: 5/Solid)

Endocrine transition. Perimenopause is a vascular inflection window. LDL rises an average of 10 to 14 mg/dL in the 12 months surrounding the final menstrual period. Blood pressure climbs. Visceral fat accumulates. Insulin sensitivity drops. These changes are biological, not behavioral, and they require recalibration of risk, not reassurance.

Subclinical inflammation. Autoimmune diseases, which disproportionately affect women, accelerate atherosclerosis. Lupus, rheumatoid arthritis, and psoriasis are independent cardiac risk factors. So is chronic sleep deprivation. So is untreated hypothyroidism. Inflammation is the engine, and women have more of it.

A risk assessment that ignores OES is incomplete. Most primary care visits ignore at least two of the three.

The Timeline: When Risk Actually Starts

Subclinical atherosclerosis begins in the 30s and 40s, often a decade before any symptom. The decade of the 50s is the danger zone. By menopause, female cardiovascular risk converges with male risk of the same age.

A Johns Hopkins analysis of U.S. mortality 1999 to 2018 found that heart disease deaths in women aged 25 to 34 rose by 2.2% per year between 2010 and 2018 Vaught 2021. Roughly one-third of all cardiovascular events in women occur before age 65. The “I’m too young for this” defense is a statistical fiction. (Honesty: 4/Promising)

For women of color, the timeline is earlier and the mortality higher. Black women have a heart disease death rate of 224 per 100,000 versus 207 for cancer. The hypertension prevalence in Black women is 58%, the highest of any demographic in the United States. The risk does not start at menopause. It started at 30 and was never measured.

The Normal-Looking Lipid Panel Trap

Most women over 40 have had a standard lipid panel: total cholesterol, LDL, HDL, triglycerides. Many have been told they are “fine.”

The standard panel is incomplete. Two women with identical LDL levels can have radically different risks.

ApoB measures the number of atherogenic particles in your blood. Each LDL, VLDL, and Lp(a) particle carries one ApoB molecule. A woman with normal LDL and high ApoB has many small, dense, particularly atherogenic particles. Her standard panel looks fine. Her arteries do not. ApoB outperforms LDL as a predictor of cardiovascular events Sniderman 2019. (Honesty: 5/Solid)

Lipoprotein(a) is a genetic variant of LDL that is highly inflammatory and pro-thrombotic. It is measured once in a lifetime because the value is genetically fixed. Elevated Lp(a) affects roughly one in five people and is a major independent risk factor for heart disease, stroke, and calcific aortic stenosis. It does not respond meaningfully to lifestyle. It is not on the standard panel. If you have never had it measured, you do not know your baseline risk.

The standard panel is a 1980s tool used in 2025. Ask for ApoB. Ask for Lp(a). Once.

The Autoimmune Amplifier: When Inflammation Is the Mechanism

The OES Triad’s third domain, subclinical inflammation, has a specific and underrecognized expression in women: autoimmune disease. The immune system’s chronic misdirection of inflammatory activity against host tissue produces a cardiovascular load that is independent of conventional risk factors and is rarely captured in standard Framingham-based risk estimates.

Systemic lupus erythematosus (SLE) sits at the extreme end of this spectrum. In a landmark analysis, Manzi and colleagues found that women aged 35 to 44 with SLE had a rate of myocardial infarction approximately 50 times higher than age-matched women in the Framingham cohort [Manzi S, AJPH, 1997]. That number is not a rounding error. Chronic complement activation, immune complex deposition in vessel walls, and the accelerated plaque formation of sustained systemic inflammation compress what would otherwise be decades of atherosclerotic progression into a compressed timeline. Women with SLE require cardiovascular risk management that diverges substantially from the standard female risk framework.

Rheumatoid arthritis (RA) does not produce the same dramatic figures as SLE, but it carries a doubling of myocardial infarction risk that renders it roughly equivalent to type 2 diabetes as a cardiovascular risk-enhancer. Solomon and colleagues, using data from the Nurses’ Health Study, found that women with RA had a relative risk of MI of approximately 2.0 after adjustment for conventional risk factors [Solomon DH, Arthritis & Rheumatism, 2003]. RA typically precedes its cardiovascular consequences by years; the inflammatory burden that drives synovial destruction is the same burden that accelerates coronary plaque formation. Statins reduce inflammatory markers in RA patients, but are underutilized in this population.

Psoriasis is often regarded as a skin condition. Cardiovascular medicine now classifies it as a systemic inflammatory disease. Large-scale analyses have found a 25–30% increase in major adverse cardiovascular events in patients with moderate-to-severe psoriasis compared with age- and sex-matched controls, independent of shared risk factors such as obesity, hypertension, and metabolic syndrome. The mechanism is the same: chronic elevation of TNF-alpha, IL-17, and IL-6 produces endothelial dysfunction, accelerates atherogenesis, and promotes thrombotic risk.

The coordination gap between rheumatology and cardiology in managing these patients is a well-documented system failure. Women with SLE, RA, or psoriasis are frequently managed within their specialty without a formal cardiovascular risk assessment that accounts for the inflammatory amplification their condition introduces. The treating rheumatologist controls the inflammation. The cardiologist, if one is involved at all, often uses a risk calculator that does not capture it. The woman in the middle receives fragmented care.

If you carry a diagnosis of SLE, RA, psoriasis, or another systemic inflammatory condition, this history belongs in your cardiovascular risk conversation alongside your lipid values and blood pressure. The inflammation is the mechanism, not the background.

What You Do This Week

The action list is short and specific.

1. Order the right labs. Request ApoB, Lp(a) (once), fasting insulin, HbA1c, hs-CRP, and a complete lipid panel. If your doctor will not order them, a direct-to-consumer lab will. The cash price is under $200 in most U.S. markets.

2. Map your blood pressure trend, not a single reading. Buy a validated home cuff. Measure morning and evening for two weeks. The trend matters more than any single visit number. A perimenopausal woman with creeping morning pressures is sounding an alarm that no annual physical will catch.

3. Document your obstetric history in writing. Preeclampsia, gestational hypertension, gestational diabetes, preterm birth, postpartum hemorrhage, recurrent miscarriage. Bring it to your next visit on paper. Do not wait to be asked.

4. Get a coronary artery calcium (CAC) score if you are over 45, or earlier with risk-enhancing factors. A CAC score of zero is one of the most powerful negative predictors in cardiology. A score above 100 changes your treatment. The test costs $100 to $200 and takes 10 minutes. (Honesty: 5/Solid)

5. Push back when told you are fine. “Normal EKG” does not exclude microvascular disease. “Normal stress test” does not exclude INOCA. “Normal angiogram” does not exclude SCAD. If your symptoms are real and persistent, the workup is not finished.

A useful script: “Given my history of [pregnancy complication / family history / perimenopause / autoimmune disease], I would like an ApoB, Lp(a), and a CAC score. If these are normal, I will be reassured. If they are abnormal, we have something to act on.”

This is not being dramatic. This is being informed.

Related Reading

• Why Women’s Heart Disease Gets Dismissed in the ER
• Cardiac Screening Tests Every Woman Over 40 Should Ask For
• Heart Disease Symptoms in Women Over 40
• Heart Disease vs Breast Cancer: The Statistics Women Don’t Hear
• The Male Longevity Gap: Why Men Die Earlier

The Next Step

The gap closes one decision at a time. Yours starts with knowing your own numbers.

Take the Stop Dying Early Women’s Cardiac Risk Assessment. It takes seven minutes. It uses the OES Triad to map your personal risk. It generates a specific lab order and screening recommendation you can take to your next visit. It is free. It is the front door of Module 1, the pillar curriculum on women’s cardiovascular prevention.

You are not being dramatic. You are being informed. That is the only difference between the women who survive this disease and the women who do not.

Frequently Asked Questions

Is heart disease really more deadly than breast cancer for women?

Yes, and the gap is not close. In the United States, roughly 305,000 women die of heart disease each year compared to about 43,000 from breast cancer. One in three women dies of cardiovascular disease. One in thirty-one dies of breast cancer. Globally,